Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company that completed its de-SPAC business combination with JATT Acquisition Corp, a blank-check vehicle sponsored by JATT Ventures that held its IPO in 2021. Operating in the biotechnology and immunology sector, Zura Bio is focused on developing treatments for autoimmune and inflammatory diseases. The 10-Q filed with the SEC on November 14, 2022, under accession number 0001410578-22-003377, reflects the company's post-merger quarterly reporting obligations as a newly public entity. To access Zura Bio's full filing history, deal timeline, and comparable SPAC transaction data, sign up for complete coverage at SpacDesk.